Related references
Note: Only part of the references are listed.Predictors of surgical approach for the management of renal cell carcinoma: a population-based study from New South Wales
Manish I. Patel et al.
ANZ JOURNAL OF SURGERY (2017)
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study
Nawar Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The impact of marital status at diagnosis on cancer survival in patients with differentiated thyroid cancer
Rong-liang Shi et al.
CANCER MEDICINE (2016)
Marital status and survival in patients with gastric cancer
Jie-Jie Jin et al.
CANCER MEDICINE (2016)
Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012
Benjamin L. Jackson et al.
BJU INTERNATIONAL (2015)
Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery
Tatum Tarin et al.
JOURNAL OF UROLOGY (2014)
Trends in the Use of Cytoreductive Nephrectomy in the United States
Che-Kai Tsao et al.
CLINICAL GENITOURINARY CANCER (2012)
The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy
Toni K. Choueiri et al.
JOURNAL OF UROLOGY (2011)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States
Claudio Jeldres et al.
UROLOGY (2009)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
Share Paper
